You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
興科蓉醫藥(06833.HK)2019年度收入達11.76億元 同比增長23.4%
格隆匯 03-30 19:18

格隆匯3月30日丨興科蓉醫藥(06833.HK)發佈年度業績,截至2019年12月31日止年度,公司實現收益約為人民幣11.764億元,同比增加約23.4%;毛利同比減少約2.3%至約人民幣2.16億元;年度溢利2289.6萬元,2018年度則虧損約人民幣2.806億元;每股基本盈利為人民幣0.014元;董事會不建議就報告期派付股息。

公告表示,得益於集團營銷工作的成效,報告期內來自於人血白蛋白注射液的銷售收益較2018年增長人民幣2.998億元,增幅約54.7%。同時,從報告期開始,集團就擁有了中國市場獨家經銷權,有關人血白蛋白由供應商在奧地利及德國工廠生產,而在去年獨家經銷權僅適用於中國的16個省份、5個自治區及3個直轄市,這便是2019年集團的人血白蛋白注射液銷售與2018年相比增長如此顯著的原因。

報告期內,來自於抗生素的銷售收益較2018年減少人民幣7040萬元,降幅約17.8%。有關減幅主要是由於該年度的安可欣產品銷售因市場競爭激烈而有所減少以及非核心產品特福猛停止銷售所致。

報告期內,其他產品貢獻收益的比例相對較低。由於集團將其資源集中在核心產品人血白蛋白注射液及抗生素業務上,因此報告期內該等產品銷售收益較2018年下降約人民幣600萬元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account